Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D

This article was originally published in RPM Report

Executive Summary

In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?


Related Content

GAIN Begins (Part 2): Infectious Disease Society and Start-Up Companies Push for More
Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
GAIN Is Great: Now Who Gets the Benefits?
An Emerging Approval Trend At FDA: More First-Time Sponsors
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs
Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle
The Politics of Drug Safety: An FDA Whistleblower's Push for Reform


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts